Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
[引用][C] Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
L Paz-Ares, D Soulières, J Moecks… - Journal of Cellular …, 2014 - produccioncientifica.ucm.es
Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
L Paz‐Ares, D Soulières, J Moecks, I Bara… - Journal of Cellular and …, 2014 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Patients with non‐small‐cell lung cancer (<
jats: styled-content style=" fixed-case"> NSCLC</jats: styled-content>) appear to gain …
jats: styled-content style=" fixed-case"> NSCLC</jats: styled-content>) appear to gain …
[PDF][PDF] Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
L Paz-Ares, D Soulieres, J Moecks, I Bara, T Mok… - J. Cell. Mol. Med, 2014 - Citeseer
Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
L Paz-Ares, D Soulières, J Moecks, I Bara… - Journal of Cellular …, 2014 - europepmc.org
Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
L Paz-Ares, D Soulières, J Moecks… - Journal of cellular …, 2014 - pubmed.ncbi.nlm.nih.gov
Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
[HTML][HTML] Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
L Paz-Ares, D Soulières, J Moecks, I Bara… - Journal of Cellular …, 2014 - ncbi.nlm.nih.gov
Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
[PDF][PDF] Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
L Paz-Ares, D Soulieres, J Moecks, I Bara… - J. Cell. Mol …, 2014 - scienceopen.com
Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
[PDF][PDF] Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
L Paz-Ares, D Soulieres, J Moecks, I Bara, T Mok… - J. Cell. Mol …, 2014 - researchgate.net
Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if …
Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
L Paz‐Ares, D Soulières, J Moecks… - Journal of Cellular …, 2014 - search.proquest.com
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …